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ABSTRACT
Here we define an important role for heat shock
factor 1 (HSF1) in the cellular response to genotoxic
agents. We demonstrate for the first time that HSF1
can complex with nuclear p53 and that both proteins
are co-operatively recruited to p53-responsive
genes such as p21. Analysis of natural and synthetic
cis elements demonstrates that HSF1 can enhance
p53-mediated transcription, whilst depletion of
HSF1 reduces the expression of p53-responsive
transcripts. We find that HSF1 is required for optimal
p21 expression and p53-mediated cell-cycle arrest
in response to genotoxins while loss of HSF1
attenuates apoptosis in response to these agents.
To explain these novel properties of HSF1 we show
that HSF1 can complex with DNA damage kinases
ATR and Chk1 to effect p53 phosphorylation in
response to DNA damage. Our data reveal HSF1 as
a key transcriptional regulator in response to geno-
toxic compounds widely used in the clinical setting,
and suggest that HSF1 will contribute to the efficacy
of these agents.
INTRODUCTION
Functioning as a transcription factor p53, in response to
various stresses including DNA damage, can control the
expression of genes involved in cell-cycle arrest, apoptosis
and DNA repair (1). For example, the cyclin-dependent
kinase inhibitor p21
Waf1/Cip1 is an important mediator of
p53-dependent cell-cycle arrest (2,3), BH3-only members
of the Bcl-2 family such as Noxa and PUMA are central to
p53-mediated apoptosis (4,5) and gadd45 is involved in
DNA repair (6). Over 50% of tumors carry inactivating
mutations in the TP53 gene encoding p53 (7).
Furthermore, many of these mutations occur within the
DNA-binding domain suggesting transcriptional activities
are critical to p53-mediated tumor suppression (8). Other
tumors may harbor aberrations that indirectly disrupt
p53. For example excessive MDM2 activity which can
result from gene ampliﬁcation (found in 7% of solid
tumors) could be a principal mechanism of p53 inactiva-
tion (9). MDM2 is an E3 ubiquitin ligase that interacts
with the p53N-terminus leading to p53 polyubiquitination
and proteosomal destruction under normal conditions
(10). Following genotoxic stress p53 can be phosphory-
lated on serine residues 15 and 20 (11,12) leading to
MDM2 dissociation, thereby stabilizing p53 and releasing
its transcriptional activity. Additional phosphorylation of
multiple p53 residues (13) combined with C-terminal acet-
ylation (14) enhances p53 transcriptional activities leading
to upregulation of genes such as gadd45, p21 and PUMA.
Recently, small molecule antagonists have been developed
that can overcome the repressive eﬀects of MDM2 on p53
thereby activating p53 in a non-genotoxic manner (15–18)
and increasing the prospect of being able to reactivate p53
in tumors. For example, the MDM2 antagonist nutlin-3, is
particularly eﬀective in causing p53-dependent apoptosis
and exhibits antitumor activity on human xenografts in
nude mice (16,19,20).
Many diﬀerent classes of proteins have been described
that can increase p53-mediated transcription including
p300/CBP (21), CARM1 (22), Set9 (23), JMY (24),
ASPP (25), and more general transcription factors such
as TBP, TAFs and Sp1 (26,27). Elegant in vitro work
has demonstrated that posttranslational modiﬁcation of
histones by p53 coactivators is required for p53-mediated
transcription from chromatin templates (22), while p53
itself is also a substrate for posttranslational modiﬁcations
by coactivators such as p300 and Set9 (14,23). To add
further complexity, new and unexpected p53-binding pro-
teins are still being discovered that can inﬂuence the tran-
scriptional activity of p53 (28–30). Our understanding of
exactly how p53 uses these cofactors remains incomplete.
Heat shock factor 1 (HSF1) belongs to a family of four
conserved transcription factors although only HSF1,
HSF2 and HSF4 are characterized in humans (31).
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shock, osmotic imbalance and geldanamycin treatment
(32,33), HSF1 is thought to trimerise and bind to heat
shock response elements (HSEs) present in heat shock
gene promoters, such as that of heat shock chaperone 70
(HSP70), which are composed of multiple adjacent and
inverse copies of the pentanucleotide motif 50-nGAAn-30
(34). HSF1 is capable of increasing the transcriptional rate
of target genes via a carboxy-terminal transactivation
domain (35,36) and interaction with transcriptional
co-regulators such as CHIP and Daxx (37,38), whereas
interaction with the HSP70 chaperone inhibits HSF1 tran-
scriptional activity through negative feedback (39).
Various studies indicate that HSF1, and its associated
factors such as CHIP and HSP70, protect cells from ther-
mal stress and point towards a prosurvival role for the
HSF1 pathway in response to hyperthermia (37,40,41).
Speciﬁcally, mice lacking HSF1 fail to elicit heat shock
protein expression in response to heat shock and do not
acquire thermotolerance in response to sublethal doses of
hyperthermia, resulting in accelerated heat shock-induced
apoptosis (42). Drosophila harboring HSF mutants also
fail to acquire thermotolerance (43). Interestingly, a recent
study has shown that whilst loss of HSF1 in p53-deﬁcient
mice lead to suppression of lymphomas, the incidence of
other tumors such as sarcomas and testicular tumors was
increased (44). Additionally, loss of HSF1 contributed to
genomic instability suggesting some overlap between p53
and HSF1 functions. Paradoxically, another study has
demonstrated that HSF1 elimination protects mice from
tumors induced by oncogenic RAS or p53
R172H and that a
range of cancer cell lines harboring various mutations
show some dependency on HSF1 for survival (45). For
some time, p53 has been known to interact with some
members of the HSF1 pathway including HSP70 and
HSP90 (46,47) and HSP90 has been shown to play an
important role in p53 transcriptional activities (48).
Here we describe a novel interaction between HSF1 and
the tumor suppressor p53 that is enhanced upon DNA
damage. We show that HSF1 is important for p53 func-
tion in cell-cycle arrest and apoptosis. These new HSF1
activities do not involve previously described properties of
HSF1 in response to heat shock, such as increased chap-
erone expression, HSF1 phosphorylation and cellular
relocalization.
MATERIALS AND METHODS
Cell culture and ﬂow cytometry
Cell lines were maintained in RPMI 1640 as described
(49). Doxorubicin, etoposide and actinomycin D and dox-
ycycline were all from Sigma. For cell-cycle analysis cells
were resuspended in PBS containing 2% FCS then per-
meabilized with 1% Triton-X-100 (Sigma), treated with
100mg/ml RNase (Sigma) and stained with 500mg/ml pro-
pidium iodide (Sigma) before analysis on a BD FACScan
instrument. For active Caspase 3 measurements FITC-
conjugated active caspase-3 antibody was used as recom-
mended (BD Pharmingen) and annexinV was purchased
from Sigma.
Immunoprecipitation, expression vectors and reporter
gene assays, immunoblotting and protein puriﬁcation
Immunoprecipitation was performed using cell extracts
as described (49), with 1mg of indicated antibody.
Recovered material was analyzed by immunoblotting.
For reporter gene assays the indicated reporter vectors
were co-transfected with 50ng of constitutively expressed
b-galactosidase reporter gene and p53 or HSF1 in
pcDNA3 (a gift from Richard Voellmy), where indicated,
using Superfect (Qiagen). Post treatment, cell extracts
were used in luciferase (Promega) and b-galactosidase
reporter assays (50). Luciferase activities were calibrated
to b-galactosidase values. For immunoblotting the follow-
ing antibodies were used; p21 Ab-1, p53 Ab-6 (Oncogene
research products), TBP Ab818 (Abcam), HSF1 Ab-1
(Neomarkers) or HSF1 SPA-901 (Stressgen), phospho
p53 #9919 (Cell Signaling). GST-tagged p53 proteins
were expressed in BL21 cells and puriﬁed according to
standard procedures.
Chromatin immunoprecipitation (ChIP) and
DNA-binding assay
ChIP was performed essentially as described (51), with
minor modiﬁcations. Before immunoprecipitation, DNA
concentrations from soluble chromatin fractions were
quantiﬁed using a Nanodrop spectrophotometer. Fifty
micrograms of this material were used per immunopreci-
pitation with speciﬁc antibodies against p53 (Ab-6,
Oncogene research products) or HSF1 (Stressgen). Post-
ChIP material and input samples were subject to quanti-
tative PCR using an Applied Biosystems 7900 system with
oligonucleotides GGATCTGTGGTAGGTGAGGGTCA
GG and GGAATTAGTCACGGGAGGCAGTGCAG
to amplify the gadd45 p53 response element (22), GGA
GTTGGAGTTGTCAGGAAAAAGGG and GGTTGT
GGTCTTTCAGGCCTCCACACC to amplify a gadd45
non-speciﬁc region 2kb downstream (22) and GTGGCTC
TGATTGGCTTTCTG and CTGAAAACAGGCAGCC
CAAG to amplify the p53 response element of p21 (3).
TransAM transcription factor assay (Active Motif) was
used to measure p53-binding activity to a consensus
sequence 50-GGACATGCCCGGGCATGTCC-30 immo-
bilized onto a 96 well plate. Assays were performed as
recommended by manufacturer.
RNAi
siRNAs against target sequences HSF1 GAGAAAGATC
CCCCTGATGdTdT and p53 GACTCCAGTGGTAAT
CTACdTdT were as described (52) and control (ns)
siRNA was as described (51). Used at a ﬁnal concentra-
tion of 5–20nM, these were transfected with HiPerFect
(Qiagen) according to manufacturers’ protocols.
Proliferation assays
WST1 reagent (Roche) was used as described by the man-
ufacturer to measure end point proliferation on cells
seeded in 96-well plates. Six replicates were used per
condition.
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Measurements of PCNA and PUMA transcript levels
were performed using Taqman products (Applied
Biosystems). p21, gadd45 and GAPDH transcript levels
were measured using SYBR Green as described (51)
with oligonucleotide sequences GTGGTAGAAATCTG
TCATGCTGGT and GACTCTCAGGGTCGAAAA
CGG for p21; CCCAAACTATGGCTGCACACT and
CCATGCAGGAAGGAAAACTATG for gadd45 and C
GACCACTTTGTCAAGCTCA and GGGTCTTACTC
CTTGGAGGC for GAPDH, respectively. Dissociation
curves conﬁrmed PCR product speciﬁcity. Transcript
quantities were corrected to values for GAPDH.
RESULTS
HSF1 interacts with p53 during genotoxic stress
Given the potential link between p53 and HSF1 (44) we
ﬁrst investigated whether p53 and HSF1 might form
protein–protein interactions. Human 293T cells that
harbor high levels of wild-type p53 due to stabilization
by SV40 DNA tumor virus large T antigen were initially
examined. Immunoprecipitation of endogenous HSF1
with polyclonal HSF1 antibody resulted in speciﬁc
co-immunoprecipitation of endogenous p53 suggesting
the proteins can complex in cells (Figure 1A). In a recip-
rocal experiment, immunoprecipitation of endogenous
p53 resulted in speciﬁc co-immunoprecipitation of endo-
genous HSF1 (Figure 1B). Additionally, immunoprecipi-
tation using HSF1 antibody recovered p53 from wild-type
MEFs, but not HSF1
–/– MEFs (Figure 1C). Finally,
immunoprecipitation using an alternative HSF1 monoclo-
nal antibody speciﬁcally recovered p53 from 293T cells
(Figure 1D). We did not ﬁnd evidence of interaction
between HSF1 and p63 (Supplementary Figure 1). We
next examined the p53-HSF1 interaction in non-virally
immortalized U2OS osteosarcoma cells that express low
p53 levels under normal growth conditions, thereby repre-
senting a more physiological setting. Under non-stressed
conditions the level of p53 that co-immunoprecipitated
with HSF1 varied from undetectable to very low in
U2OS cells (Figure 1E and data not shown). However,
after treatment of cells with the genotoxic compounds
actinomycin D, doxorubicin or etoposide that stabilize
p53, HSF1 could be eﬃciently co-immunoprecipitated
with p53 (Figure 1E). Notably, exposure of U2OS cells
to varying degrees of hyperthermia or geldanamycin did
not increase either intracellular levels of p53 or the inter-
action between HSF1 and p53 (data not shown) suggest-
ing that p53–HSF1 interactions are modulated by
genotoxic stress but not by heat shock. In order to delin-
eate the region of p53 that would interact with HSF1, we
next assessed the ability of HSF1 to interact with p53
deletion mutants in a GST pull-down assay. HSF1 could
interact with full-length p53 as well as residues 1–292, but
not an N-terminal deletion mutant lacking residues 1–248
(Supplementary Figure 2). Additionally, HSF1 retained
interactions with a proline-rich domain deletion mutant
but did not interact with residues 1–42 that contain the
p53 transactivation domain (Supplementary Figure 2).
This suggests that the region on p53 that interacts with
HSF1 lies between residues 42–248, which includes the
DNA-binding domain of p53. We were unable to more
ﬁnely delineate a single interaction site on p53; further
experiments suggested that HSF1–p53 interactions might
be multiple and complex. It is unknown how much HSF1
is interacting with p53 in these experiments.
We next wanted to examine whether HSF1 might be
activated by DNA damaging agents in a similar manner
to heat shock. Previous studies have demonstrated that
HSF1 can undergo phosphorylation in response to
hyperthermia which correlates with HSF1 accumulation
in nuclear bodies and increased HSF1 target gene expres-
sion (31,53–55) and references therein. We assessed the
nuclear:cytoplasmic ratio of HSF1 in response to doxo-
rubicin or heat shock. In untreated U2OS cells HSF1 was
present in both nuclear and cytoplasmic fractions and
little evidence of HSF1 hyperphosphorylation was present
(Figure 1F). As expected HSF1 hyperphosphorylation,
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Figure 1. HSF1 interacts with p53. (A) Extracts from 5 10
5 293T
cells were subject to immunoprecipitation with HSF1 polyclonal anti-
sera or irrelevant FRS2 antibody (irr). Recovered material was immu-
noblotted with HSF1 polyclonal antisera or p53 monoclonal antibody.
*Indicates IgG band. (B) Same as in (A) except that p53 polyclonal
antisera was used for immunoprecipitation and monoclonal antibodies
against HSF1 or p53 were used for immunoblotting. **Likely p53
degradation product. (C) HSF1
+/+ or HSF
–/– MEFs were used for
immunoprecipitation as in (A) (D) 293T cells were used for immuno-
precipitation with monoclonal HSF1 antibody as in (A) (E) U2OS cells
were treated with actinomycin D (5, 50 or 500nM) or doxorubicin (0.1,
0.5 or 5mM) or etoposide (1, 50 or 100mM) for 12h. Cells lysates were
then subject to immunoprecipitation and immunoblotting as in (A).
Unt denotes untreated. (F) U2OS cells were heat shocked at 43 C for
2h or treated with 0.5mM doxorubicin (dox). Cytoplasmic (C) and
Nuclear (N) extracts were then prepared and analyzed by immunoblot-
ting with antibodies as used in (E). TBP occurrence conﬁrmed com-
partment separation.
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upon heat shock (Figure 1F, lane 3 and 4), however no
signiﬁcant change in HSF1 phosphorylation or nuclear
enrichment was detected after treatment of U2OS or
HCT116 cells with doxorubicin or other genotoxins
(Figure 1F and data not shown). We additionally exam-
ined the expression levels of HSF1 target chaperone genes
in response to heat shock or genotoxic stress in U2OS
cells. As expected, we detected large increases in Hsp70
and Hsp27 transcript levels by quantitative RT–PCR in
response to heat shock (46-fold and 32–fold, respectively),
but no signiﬁcant changes were observed in response to
doxorubicin or etoposide at the doses used (data not
shown). This suggests that the well-established role of
HSF1 in regulating chaperone expression, as part of the
heat shock response, is probably not relevant in the
response to chemotherapy. We cannot completely rule
out this alternative mechanism, as even small changes in
HSP transcript and/or protein levels may play a role in
p53 activation.
HSF1 regulates p53-mediated transcription
Previous studies have shown that HSF1 can upregulate
pro-survival genes in response to heat shock whereas
p53 can regulate pro-apoptotic genes in response to
genotoxic stress. However, no study has examined
HSF1-mediated transcription in response to genotoxic
stress. Given that p53 and HSF1 interact in a manner
that can be inﬂuenced by genotoxic stress we speciﬁcally
examined what role HSF1 might play in p53-regulated
transcription.
First, to get an overview of whether HSF1 is involved in
expression of p53 target genes, we depleted cells of HSF1
by means of RNAi then measured steady state levels of
p53 target gene transcripts. Speciﬁc siRNA targeted
towards HSF1 was used and cells transfected with p53
or non-silencing siRNAs served as controls. Depletion of
p53 resulted in dramatic loss of p21 transcript expression
to almost undetectable levels compared to control samples
(Figure 2A) as measured by quantitative RT–PCR.
Depletion of HSF1 also produced a striking decrease in
p21 transcript levels suggesting p53 and HSF1 regulate
p21 expression in a similar manner (Figure 2A).
Analysis of the p53-responsive gadd45, PUMA and
PCNA transcripts showed varied levels of reduced expres-
sion upon either p53 or HSF1 depletion (Figure 2A). We
next wanted to determine whether HSF1 might be
required for dynamic changes in p53 target gene expres-
sion that occur in response to genotoxins that activate
p53. p21 transcript levels increased in a dose-dependent
manner in response to etoposide or actinomycin D in
U2OS cells (Supplementary Figure 3). Doxorubicin
could also induce p21 expression, but only in the lower
dose range (Supplementary Figure 3). siRNAs for p53 and
HSF1 were again transfected and U2OS cells were then
challenged with etoposide, doxorubicin or actinomycin D
to induce p53 responsive genes. Silencing either p53 or
HSF1 resulted in a blunted response to chemotherapy;
cells could not increase p21 transcript levels to the same
degree as control transfectants (Figure 2B). As expected,
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Figure 2. HSF1 regulates expression of p53 target genes. (A) siRNA
targeting p53 or HSF1 or non-silencing (ns) siRNA were transfected
into U2OS cells in 12-well plates. Seventy-two hours later cells were
harvested and total RNA was puriﬁed and used to generate cDNA.
Quantitative realtime PCR was performed on cDNA for the indicated
gene transcripts. (B) U2OS cells in 12-well plates were transfected with
indicated siRNAs then 48h later treated with etoposide (100mM), acti-
nomycin D (1nM) or doxorubicin (0.1mM) overnight then used as in
(A). (C) U2OS cells were transfected with the indicated siRNAs and
treated with 0.1mM or 0.5mM doxorubicin as in (B). Equal quantities
of whole-cell extracts were used for immunoblotting with the indicated
antibodies. (D) Wild-type (+/+) or HSF1 null (–/–) MEFs were trea-
ted with 0.1mM doxorubicin where indicated and used as in (C). Error
bars represent standard deviation.
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script levels (Figure 2B).
To ascertain whether these eﬀects could be detected at
the protein level the expression of p21 protein was mea-
sured in extracts produced from cells transfected with the
siRNAs. Depletion of HSF1 substantially reduced both
steady-state levels of p21 and induction of p21 protein
expression mediated by doxorubicin, without aﬀecting
p53 protein levels (Figure 2C). Similarly, p53 depletion
partly abrogated the induction of p21 protein
(Figure 2C). These data suggest that HSF1 is important
for expression of p21 in response to chemotherapy. To
validate this suggestion we examined p21 expression in
MEFs that lack HSF1. In response to doxorubicin wild-
type MEFs expressed a readily detectable amounts of p21
protein yet HSF1
–/– MEFs did not (Figure 2D).
We wanted to delineate whether HSF1 could alter the
expression of p53 targets by modulating p53 transcrip-
tional activities or by aﬀecting these genes via some
other mechanism. To do this we ﬁrstly studied p53
cis-regulatory elements. Two reporter genes were ini-
tially used that contain either consensus p53-binding
sequences (termed PG13) or mutated, non-functional,
sequence (termed MG15). These reporter genes were
transfected into a p53-deﬁcient background of HCT116
p53
–/– cells (2). As expected, co-transfection of increasing
amounts of exogenous p53 resulted in increases in PG13
reporter gene activity, but no increase in MG15 reporter
gene activity (Supplementary Figure 4) and 1ng of exog-
enous p53 was suﬃcient to enhance PG13 2.5-fold.
Interestingly, co-transfection of increasing amounts of
HSF1 further enhanced p53-induced reporter gene activity
(Figure 3A). This enhancement by HSF1 was not
observed in the absence of co-transfected p53
(Figure 3A). Additionally, treatment with 0.5mM doxor-
ubicin led to increases in reporter gene activity, which
could be further enhanced by co-transfection of HSF1
(Figure 3A). As expected, p300 transfection also produced
some increase in reporter gene expression (Figure 3A). No
signiﬁcant changes in reporter activity were observed with
the MG15 reporter gene either in the presence of p53,
HSF1 (Figure 3A) or doxorubicin (data not shown).
These observations suggest that HSF1 overexpression
can increase p53 transcriptional activity and that mutation
of the p53-binding sequence is suﬃcient to abrogate the
eﬀects of HSF1 on p53-binding cis elements. We next
assessed whether depletion of HSF1 would result in
reduced p53 reporter gene expression. U2OS cells that
harbor wild-type p53 were transfected with siRNA target-
ing either p53 or HSF1 or luciferase as an internal control,
whereas non-silencing (ns) siRNA was used as a negative
control. Additionally, cells were treated for 12h with gen-
otoxic agents to further induce reporter gene activity
before harvesting. As expected, p53 or luciferase silencing
followed by transfection of the PG13 or p21 reporter
genes resulted in large reductions in reporter gene activity
compared to control transfectants (Figure 3B). HSF1
silencing also resulted in a striking reduction in reporter
gene activity in either untreated or genotoxin treated cells
(Figure 3B).
Having shown an eﬀect of HSF1 on p53 target gene
expression and transfected reporter genes containing iso-
lated p53 response elements, we next examined recruit-
ment of HSF1 and p53 to natural gene promoters by
quantitative ChIP. This would enable us to determine
whether HSF1 is recruited to the promoter regions of
native p53 target genes, thus aﬀecting p53-dependent
expression at the transcriptional level. As shown pre-
viously, treatment of cells with genotoxins resulted in
increased recruitment of p53 to the p21 and gadd45 pro-
moter (2,22,56). Interestingly, HSF1 recruitment to the
p21 and gadd45 promoters could also be detected under
basal conditions, which underwent a large increase in
response to doxorubicin, actinomycin D or etoposide
(Figure 4A and Supplementary Figure 5). To conﬁrm spe-
ciﬁcity, we tested recruitment of p53 or HSF1 to a non-
speciﬁc region of the gadd45 gene, 2kb downstream from
the gadd45 promoter. Only background levels of binding
were found at this region, which did not show signiﬁcant
enrichment upon genotoxin treatment of cells (Figure 4A)
suggesting that HSF1 and p53 binding to the p53 response
elements was speciﬁc in our assay. Additionally, ChIP
with irrelevant antibody (irr) recovered only background
levels of DNA (Figure 4A). Next, we wanted to assess the
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Figure 3. HSF1 enhances p53 transcriptional activities (A) HCT116
–/–
cells were transfected in 48-well plates with 100ng of the indicated
reporter gene with or without 1ng p53 and with either empty vector
or increasing amounts of HSF1 (10, 20, 40, 80 or 160ng) or 160ng
CMV-p300. Forty-eight hours later cells were treated for 12h with
doxorubicin (dox) where indicated then harvested for reporter gene
assays. Transfections were performed in quadruplicate in three indepen-
dent experiments. (B) U2OS cells in 24-well plates were transfected with
the indicated siRNAs. After 24h cells were split into 48-well plates then
transfected with 200ng of p21-luc reporter. Twenty-four hours later
cells were treated with actinomycin D (1nM), doxorubicin (0.5mM)
or etoposide (50mM) for 12h then harvested for reporter gene assays.
Error bars represent standard deviation.
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recruitment to p53 target gene promoters. Comparison
of isogenic p53-proﬁcient (HCT116
+/+) and p53-deﬁcient
(HCT116
–/–) cell lines showed that while a low level of
HSF1 could be recruited to the p21 promoter in the
absence of p53, drug induced increases in HSF1 binding
occurred only in p53-proﬁcient cells (Figure 4B). We also
examined the interdependency of p53 and HSF1 for
recruitment to the p21 and gadd45 promoters using
siRNA (Figure 4C). Congruent with the data from
HCT116 cells, p53 knockdown substantially reduced
HSF1 binding to either of the endogenous p53 response
elements within the p21 or gadd45 promoters in U2OS
cells treated with doxorubicin (Figure 4C and
Supplementary Figure 6). Conversely, HSF1 knockdown
also resulted in a large reduction of p53 recruitment to the
gadd45 or p21 p53 response elements (Figure 4C). We
additionally examined the eﬃciency of p53 binding to a
consensus DNA sequence by ELISA. First, p53 from wild-
type MEF nuclear extracts showed a 6.7-fold increase in
DNA binding in response to doxorubicin, whereas no
increase was observed in HSF1
–/– MEFs (Figure 4D).
Secondly, HSF1 or p53 siRNA-mediated knockdown in
U2OS cells produced a striking reduction in p53 DNA-
binding activity (Figure 4D) in response to doxorubicin.
HSF1 is involved in p53-mediated growth regulation
p53 can induce cell-cycle arrest and apoptosis in a manner
dependent upon its competence as a transcription factor
and murine HSF1 has previously been shown to be
required for heat shock-mediated G2/M arrest (57).
Having observed some dependency for HSF1 in p53-
mediated transcriptional regulation we next assessed the
contribution HSF1 might have to p53-mediated growth
arrest.
We ﬁrstly assessed the eﬀects of genotoxic compounds
on MEF cell cycle. Strikingly, etoposide and doxorubicin
could invoke a dramatic G2/M checkpoint cell-cycle arrest
in wild-type MEFs but not in HSF1
–/– MEFs (Figure 5A).
We next wanted to examine if human HSF1 would act
similarly in cancer cells. First, U2OS cells were treated
with the same compounds and showed a G2/M arrest,
as expected (Figure 5B). Intriguingly, p53 or HSF1 deple-
tion blunted this response to genotoxic stress; cells did not
arrest as readily as judged by diminished increases in
G2/M checkpoint populations in response to etoposide
or doxorubicin (Figure 5C). In order to examine whether
this eﬀect was dependent upon p53, we next analyzed p53
deﬁcient and proﬁcient cells. In response to doxorubicin
HCT116
+/+ p53 proﬁcient cells transfected with non-
silencing siRNA demonstrated a G2/M arrest, however
HSF1 knockdown completely abrogated this eﬀect
(Figure 5D). In agreement with previous studies (2,58)
HCT116
–/– p53 deﬁcient cells were still capable of eﬃcient
G2/M arrest in response to doxorubicin. Strikingly, HSF1
siRNA transfection did not aﬀect G2/M arrest in
HCT116
–/– p53 deﬁcient cells (Figure 5D). This suggests
that HSF1-mediated cell-cycle arrest in response to dox-
orubicin is p53-dependent. In order to examine the impact
of HSF1 on cellular proliferation we compared MEFs
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Figure 4. HSF1 is recruited to p53 target gene promoters (A) U2OS
cells in 90mm dishes were treated overnight with etoposide (1mM),
doxorubicin (0.5mM), actinomycin D (50nM) then used for ChIP
with HSF1, p53 or irrelevant FRS2 antibody (irr). Subsequent quanti-
tative real-time PCR was performed on the p21 promoter or a non-
speciﬁc sequence downstream from the gadd45 gene promoter referred
to as ‘non-speciﬁc’. Data are expressed as fold change. (B) HCT116
cells lacking p53 (–/–) or harboring wild-type p53 (+/+) were treated
as in (A) with increasing doses of doxorubicin (0.1, 0.5 or 5mM), etopo-
side (0.1, 1 or 100mM) or actinomycin D (1, 5, 50 or 500nM) then
subject to ChIP. Data are expressed as fold change for each cell line.
(C) U2OS cells in 90mm dishes were transfected with the indicated
siRNAs. Forty-eight hours later cells were treated for 12h with either
0.5mM doxorubicin then subject to ChIP with HSF1 or p53 antibodies.
Data are expressed as a proportion of maximal observed recruitment.
Experiments were performed three times. Data represent one experi-
ment. Error bars represent standard deviation. (D) Left panel:
Nuclear extracts from wild type or HSF
–/– MEFs treated with 0.5mM
doxorubicin or vehicle were used in p53 DNA-binding assay. Data are
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used in the p53 DNA-binding assay and data are represented as fold
increase above vehicle treated cells.
Nucleic Acids Research,2009, Vol.37, No. 9 2967lacking HSF1 to wild-type MEFs. The concentration of
doxorubicin required to produce a 50% decrease in pro-
liferation in wild-type MEFs was approximately 250nM,
compared to 5mM in HSF1
–/– cells (Figure 5E). Wild-type
MEFs were also more sensitive to etoposide and actino-
mycin D than HSF1
–/– MEFs (Figure 5E and data not
shown).
To speciﬁcally study p53-mediated growth arrest and to
be certain that HSF1 was required for p53-mediated
changes in cell growth we utilized an alternative system.
Rather than employ additional p53-activating drugs, that
might have secondary eﬀects on cells, we used SAOS2
osteosarcoma cells stably transfected with a doxycycline-
inducible p53 vector (59), termed SAOS-tetWTp53 cells.
First, we established that addition of 0.1mg/ml doxycy-
cline was suﬃcient to produce a 50% decrease in prolifer-
ation of SAOS-tetWTp53 cells (data not shown). Next we
assessed the contribution of HSF1 to this growth arrest.
Although very high transfection frequencies could not be
achieved in these cells, transfection of p53 siRNA inhib-
ited the reduction in proliferation from 53% to 70% and
HSF1 depletion had the same eﬀect (Figure 6A). We also
examined apoptosis and found that addition of 0.1mg/ml
doxycycline to SAOS-tetWTp53 cells produced an 11-fold
increase in apoptotic cell numbers from to 5% to 55%
(Figure 6B), measured by ﬂow cytometry using the
active caspase-3 marker. Inspection of cell morphology
also revealed widespread membrane blebbing upon p53
induction (data not shown). Depletion of HSF1 or p53
partly diminished this response resulting in fewer apopto-
tic cells after doxycycline treatment (Figure 6B). These
data indicate that loss of HSF1 can speciﬁcally interfere
with p53-induced growth arrest and apoptosis. Lastly, we
compared apoptosis in MEFs lacking HSF1 to wild-type
MEFs using annexinV staining and ﬂow cytometry. In
response to etoposide we measured  90% of wild-type
MEFs to be annexinV positive compared to 55% in
HSF1
–/– cells (Figure 6C). Addition of actinomycin D
produced 80% annexinV positive wild type MEFs com-
pared to 30% in HSF1
–/– cells (Figure 6C).
HSF1 interacts with DNA damage kinases and facilitates
p53 phosphorylation
Finally, in order to delineate a precise mechanism by
which HSF1 might confer sensitivity to chemotherapy
we examined post-translational modiﬁcation on p53.
Doxorubicin is well known to induce phosphorylation of
multiple serine residues on p53 which are likely to contrib-
ute to its eﬃcacy as a transcription factor (13). First, we
examined the phosphorylation status of p53 in HSF1
immunoprecipitated material. Using phospho-speciﬁc
p53 antibodies we found that p53 modiﬁed on serine 6
and serine 15 exhibited strong increases in HSF1 interac-
tion in response to doxorubicin, whilst other modiﬁed
forms of p53 such as serine 9 modiﬁed p53 did not interact
as markedly upon DNA damage (Figure 7A). We next
examined whether DNA damage kinases that are known
to mediate the phosphorylation of p53 could complex with
HSF1. Although we found no evidence of an interaction
with ATM or DNA-PK (data not shown) we could
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Figure 5. HSF1 is required for cell-cycle arrest in response to p53
activating agents (A) Wild-type or HSF
–/– MEFs were treated with
0.5mM doxorubicin or 1mM etoposide for 12h then stained with
propidium iodide and injected into ﬂow cytometer. (B) U2OS cells in
12-well plates were treated overnight with increasing doses of genotoxic
drugs or left untreated (Unt) then used as in (A). (C) U2OS cells were
transfected with the indicated siRNAs then 48h later treated with the
indicated drugs overnight. Cells were then used as in (A). Percentage
change in G2/M phase are presented from one of three experiments.
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assays were then performed. Six replicates were used for each condition
and error bars represent standard deviation.
2968 Nucleic Acids Research, 2009,Vol.37, No. 9reproducibly co-immunoprecipitate HSF1 with Chk1 or
ATR (Figure 7B and C), both of which are known to
mediate phosphorylation of serine 6 and serine 15 on
p53 (60). The HSF1–Chk1/ATR complex was not altered
upon treatment with doxorubicin whilst HSF1–p53 inter-
action was only readily detectable in the presence of dox-
orubicin (Figure 7B). We next tested whether loss of HSF1
ser15
HSF1
p53
ns          HSF1
Tubulin
– + – + dox
ser15
Tubulin
–/– +/+ –/– +/+ –/– +/+ MEF
– 0.1 0.5 dox(uM)
Input
IP
Chk1
HSF1
p53
–+ + – ++
HSF1 irr
dox
ser15
Input
IP
ser6
ser9
HSF1    irr
–+ + –+ +
A
B
C
D
E
DNA damage
Active p53
Chk1 HSF1
ATR
p53
Normal
Inactive p53
Chk1 HSF1
ATR
p53
F
dox
dox HSF1
–++
ATR  IP   irr
dox
Figure 7. HSF1 aﬀects p53 phosphorylation status. (A) HCT116 cells
were treated with 0.5mM doxorubicin where indicated for 12h before
immunoprecipitation (IP) with HSF1 monoclonal antibody or irrele-
vant antibody (irr). Material was then immunoblotted as indicated.
(B) HCT116 cells were treated as in (A) and immunoprecipitated mate-
rial was immunoblotted with the indicated antibodies. (C) HCT116
cells were treated as in (A) then subject to immunoprecipitation with
ATR antibody. Material was then immunoblotted for HSF1. (D)
HCT116 cells were transfected with indicated siRNA then after 48h
treated with 0.5mM doxorubicin for 12h. Equal quantities of whole-cell
lysates were then immunoblotted as shown. (E) Wild-type or HSF
–/–
MEFs seeded in 12-well plates were treated with the indicated dose of
doxorubicin before equal quantities of cell lysate were immunoblotted
as in (D). (F) Model of HSF1 modulation of p53 before and after DNA
damage.
s
i
R
N
A
Relative proliferation
02 0 4 0 6 0 8 0 1 0 0
53
72
70
ns
p53
HSF1
doxy
unt
7 6 6 8
50
29
24
32
0
10
20
30
40
50
60
ns HSF1 p53 p300 siRNA
%
 
C
a
s
p
a
s
e
 
3
 
+
v
e
 
c
e
l
l
s
doxy
unt
Unt                Doxy
Caspase 3
F
I
T
C
B
A
C
MEF +/+
MEF –/–
Unt                etop ActD
FITC FITC FITC
Annexin V
Figure 6. HSF1 is involved in p53-mediated apoptosis (A) SAOS2-
tetWTp53 cells seeded into 48-well plates were transfected with indi-
cated siRNAs. Twenty-four hours later cells were split into 96-well
plates then treated with 0.1mg/ml doxycycline (doxy) for 48h before
proliferation was measured using WST-1 assay. (B) Upper panel: Saos2-
p53 cells in 12-well plates were treated for 36h with 0.1mg/ml doxy
(right) or left untreated (left) before analysis of active caspase-3 by ﬂow
cytometry. Events in upper region represent active caspase-3 staining.
Lower panel: SAOS2-tetWTp53 cells were transfected with the indicated
siRNAs. After 48h cells were treated for a further 36h with 0.1mg/ml
doxy or left untreated then analyzed as before. Percentage of active
Caspase-3 positive cells is shown from one of three experiments
(lower panel). Error bars represent standard deviation. (C) Wild-type
or HSF
–/– MEFs seeded in 6-well plates were treated with 50mM etopo-
side or 50mM actinomycin D for 48h before harvesting and staining for
FITC-conjugated AnnexinV.
Nucleic Acids Research,2009, Vol.37, No. 9 2969might inﬂuence the phosphorylation of p53. HCT116
cells were transfected with HSF1 siRNA and treated
with doxorubicin. Compared to control cells transfected
with non-silencing siRNA we found that phosphoryla-
tion of serine 15 was reduced upon depletion of HSF1
(Figure 7D). Additionally, we tested MEFs lacking
HSF1. Whilst both wild-type and HSF1
–/– MEFs
expressed p53 (Figure 2D) only in wild-type cells did
p53 undergo phosphorylation on serine 15 (Figure 7E).
Immunoﬂuorescence using phospho-serine 15 also demon-
strated a nuclear accumulation of serine 15 phosphoryla-
tion in wild-type MEFs which was absent in HSF1
–/–
MEFs (Supplementary Figure 7).
DISCUSSION
Here we deﬁne a novel role for HSF1 in the regulation of
the tumor suppressor p53. We propose that HSF1 is
required for the steady-state expression of a number of
p53-responsive genes, but is also required for dynamic
changes in expression of at least one critical p53 target
gene, p21, on which HSF1 appears to function as an obli-
gate p53 cofactor.
p53 can be activated by a wide variety of diﬀerent sig-
nals such as DNA double strand breaks, inhibition of
RNA production and pharmacological inhibition of
MDM2. Yet, p53 is somehow able to co-ordinately regu-
late the expression of distinct subsets of genes depending
upon the activating signal. Exactly how p53 is able to
perform this remarkable function remains to be fully
explained, although elegant studies have shown gene-
speciﬁc mechanisms to exist such as the requirement for
P-TEFb and RNA polII phosphorylation (61) and signal-
speciﬁc recruitment of basal transcriptional machinery
including TAFII250 and TFIIB to p53 target genes (62).
Here, we found that diﬀerent classes of compound that
stabilize and activate p53 via distinct mechanisms require
HSF1 in order to fully elicit their eﬀects. Actinomycin D
inhibits RNA polymerase I, thereby blocking ribosomal
biogenesis and activating p53 through a non-classical
pathway (61) that does not alter phosphorylation of
N-terminal p53 serine residues (63). Doxorubicin and eto-
poside act in a diﬀerent manner; by inhibiting topoisom-
erase activities thereby causing DNA double strand breaks
which subsequently results in phosphorylation of
p53N-terminal p53 serine residues. However, in response
to actinomycin D, doxorubicin or etoposide the interac-
tion between HSF1 and p53 was increased suggesting that
simply increasing the intracellular concentration of p53
may be suﬃcient to enable HSF1–p53 complex formation.
We also demonstrate that induction of p21 gene expres-
sion and associated cell-cycle changes generated by these
agents are dependent, at least in part, on HSF1. This
could imply that HSF1 is a universal regulator of p53
function, independent of the p53 activating signal. In a
recent study, downregulation of HSF1 in HeLa cells did
not result in altered sensitivity to the chemotherapeutic
genotoxin cisplatin (64). These cells are functionally deﬁ-
cient in p53 due to expression of the papillomavirus E6
protein. Our reporter gene assay and ChIP data from the
HCT116–derived cell lines suggest that HSF1-mediated
responses to chemotherapy are indeed dependent upon
p53, which would explain the lack of altered drug sensi-
tivity in HeLa cells.
Our ChIP studies, in keeping with other reports, showed
that a basal level of p53 was present at the p21 promoter
under non-stressed conditions but also that HSF1 was
present under these conditions. This might provide a
mechanism by which HSF1 and p53 can co-ordinately
regulate inducible gene expression before further recruit-
ment of the two factors in response to continued stress.
Additionally, this would explain why HSF1 knockdown
reduces p21 levels in unstressed cells. Strikingly, depletion
of either HSF1 or p53 resulted in loss of recruitment of
both factors to the p21 or gadd45 promoters suggesting
that HSF1 and p53 are recruited co-operatively, in an
interdependent manner. The mechanism by which HSF1
enhances p53 transcriptional activity could involve either
increased recruitment of p53 to p53 response elements or
activation/recruitment of additional factors such as HSPs
that might facilitate p53 DNA binding. In keeping with
the former model, our protein interaction data show that
HSF1 binds near to, or in, the central DNA-binding
domain of p53 which might facilitate p53–DNA interac-
tions. However, we cannot dismiss the fact that HSF1
might also play an indirect role in p53 activation via
HSPs which have previously been shown to be important
for p53 folding, DNA binding and transcriptional activity
(47,48).
In order to provide a more detailed mechanism by
which HSF1 activates p53 we examined p53 phosphoryla-
tion in response to doxorubicin. p53 can be phosphory-
lated by multiple kinases including ATM (65,66), ATR
(65,67), DNAPK (68) and CKII (69) on residues modiﬁed
in response to DNA damage (11). HSF1 was required for
phosphorylation of serine 15 on p53, but was not required
for phosphorylation of other p53 serine residues. In some
experiments we observed a reduction in serine 6 phosphor-
ylation on p53 in response to HSF1 depletion however this
was not always reproducible (data not shown). Our data
show that HSF1 complexes with ATR and Chk1 which
can phosphorylate p53 on residues 15 and 6 (60,70).
Unlike the interaction with p53, the association of these
kinases with HSF1 were not increased in response to dox-
orubicin. We therefore suggest that HSF1–Chk1–ATR
form a steady-state complex that conditionally interacts
with p53 in response to DNA damage to eﬀect p53 phos-
phorylation (Figure 7F). We anticipate that there must
also be other mechanisms by which HSF1 can activate
p53 in response to signals such as actinomycin D which
does not induce p53 phosphorylation. The indirect path-
way referred to above, in which HSF1 could modulate
HSP chaperone activities leading to p53 activation, is
one putative mechanism.
Given previously published data derived from HSF1
deﬁcient mice describing a pro-survival role for HSF1 in
response to heat shock, we were surprised to discover that
HSF1 can promote not only cell-cycle arrest but also p53-
mediated apoptosis. Two recent studies have shown that
HSF1 has a pro-apoptotic function, albeit in spermato-
genesis. Transgenic mice expressing constitutively active
2970 Nucleic Acids Research, 2009,Vol.37, No. 9HSF1, either globally or restricted to spermatocytes, exhi-
bit arrested spermatogenesis and abundant spermatocyte
apoptosis, despite increased expression of HSPs (71,72).
This eﬀect was associated with increased levels of p53
and p53-responsive response genes of the Bcl-2 family
(72) thereby providing another potential link between
p53 and HSF1 pathways. Taken together with our data
showing that HSF1 knockdown reduces PUMA levels this
aﬀords a transcriptional mechanism by which HSF1 could
regulate p53-mediated apoptosis and suggests that a thor-
ough assessment of the role of HSF1 in p53-mediated
apoptosis should be undertaken. Intriguingly, HSF1 has
recently been shown to be required for tumorigenesis in
mice harboring activated oncogenes including RAS or
p53
R172H (45) which points towards a putative oncogenic
role for HSF1. Notably however HSF1 overexpression
alone was insuﬃcient to promote cellular transformation;
potent oncogene activation was also required (45).
Although some of these results may seem diﬃcult to rec-
oncile with our data, the ﬁndings are not contradictory to
ours because we have examined the role of HSF1 in
response to DNA damage rather than oncogene activa-
tion. Taken together, the data show that in response to
DNA damage in wild-type p53 cells, HSF1 promotes cell-
cycle arrest and apoptosis whereas in cells containing pow-
erful oncogenes HSF1 function is redirected to promote
cell survival and tumorigenesis. Therefore, it would
appear HSF1 can contribute to both pro- and anti-apop-
totic pathways and what role HSF1 plays is dependent on
the cellular context.
Since our data suggest that p53 and HSF1 have a
common role in response to DNA damage, it would be
useful to examine whether or not human cancers retain
expression of wild-type HSF1 in the absence of p53 muta-
tions. We speculate that mutations in HSF1 which inhibit
the functions described herein would confer a growth
advantage on tumor cells undergoing chemotherapy, a
hypothesis yet to be explored. We have not yet investi-
gated whether other members of the HSF family are capa-
ble of activating p53.
In summary, this study has uncovered a new role for
HSF1 in the cellular response to stresses that activate p53.
To deﬁne the precise mechanism(s) by which HSF1 can
regulate p53-mediated transcription and apoptosis in
response to multiple signals represents the next major
challenge in understanding the complex functions of
HSF1.
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